Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areas

• Published in: Archives of dermatological research Vol. 316; no. 6; p. 272
• Main Authors: Michelucci, A., Margiotta, F. Manzo, Cartocci, A., Panduri, S., Trovato, E., Calpalbo, E., Dragotto, M., Di Cesare, A., Rosi, E., Rossari, S., Magnano, M., Pescitelli, L., Buggiani, G., Simoni, B., Lorenzoni, E., Ricceri, F., Savarese, I., Milanesi, N., Rubegni, P., Prignano, F., Romanelli, M.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 25.05.2024; Springer Nature B.V
• Subjects: Adult; Aged; Antibodies, Monoclonal - therapeutic use; Dermatology; Female; Humans; Inflammation; Interleukin 23; Italy; Male; Medicine; Medicine & Public Health; Middle Aged; Monoclonal antibodies; Psoriasis; Psoriasis - drug therapy; Research Letter; Retrospective Studies; Severity of Illness Index; Survival; Survival analysis; Treatment Outcome; Italy; Risankizumab; Psoriasis; Drug survival; Hard-to-treat areas
• ISSN: 1432-069X; 0340-3696; 1432-069X
• DOI: 10.1007/s00403-024-03146-2

Psoriasis, a chronic inflammatory condition, often presents challenges in treatment, particularly in areas such as nails, palms/soles, scalp/face, and genitalia. Monoclonal antibodies (mAb) like risankizumab targeting interleukin-23 (IL-23) have emerged as promising treatments, yet data on long-term efficacy remain limited. This multicenter retrospective study aimed to evaluate the drug survival at 12 and 36 months of 191 psoriasis patients treated with risankizumab, focusing on critical areas. Patients, previously unresponsive to first-line therapies, were treated according to Italian Guidelines. Survival analysis revealed a 97.6% one-year and 95% three-year drug survival rate. Secondary ineffectiveness was the primary reason for discontinuation, particularly in palmoplantar involvement cases. Factors such as BMI, gender, age, disease duration, baseline severity, and previous biologic exposure did not significantly impact drug survival, except for palmoplantar psoriasis (HR 4.72). Risankizumab demonstrated prolonged response with low treatment switch requirements, especially notable in challenging areas. Understanding such factors can aid in optimizing therapeutic approaches for improved patient care and long-term outcomes in managing psoriasis. Further research is warranted to refine treatment strategies in difficult-to-treat areas.